Compare Amylx Pharmaceuticals Inc (AMLX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Wix.Com Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Wix.Com Ltd trades at $69.24 (market cap $2.79B). The key difference: Amylx Pharmaceuticals Inc and Wix.Com Ltd are close in size by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| AMLX | WIX | |
|---|---|---|
Market Cap | $2.64B | $2.79B |
Sector | Health | Technology |
52-Week High | $24.19 | $184.24 |
52-Week Low | $7.82 | $40.43 |
Enterprise Value | $2.39B | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
WIX stock trades at $68.78, up 10.18% today, with a bullish technical signal from moving averages. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19%, and the company faces a securities class action. The P/E ratio is elevated at 62.84, indicating high growth expectations. Recent news highlights the launch of Symphony by Wix, an AI system for SMBs, amidst legal challenges.
The outlook is mixed: strong analyst consensus (65.85% buy rating) and a $79.75 price target suggest upside, but legal risks and negative cash flow in 2025 pose significant headwinds. Investors should weigh growth potential against execution and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
